Syndax Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGSyndax Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 36), showing significant lag compared to the market leaders. Earnings growth of 100% provides fundamental context to the price action. Investors should exercise caution due to high volatility (57% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $18.65 | +1.89% | ABOVE |
| 50 SMA | $20.46 | -7.15% | BELOW |
| 100 SMA | $21.38 | -11.12% | BELOW |
| 150 SMA | $20.91 | -9.12% | BELOW |
| 200 SMA | $19.50 | -2.54% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SNDX in an uptrend right now?
SNDX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is SNDX overbought or oversold?
SNDX's RSI (14) is 49. The stock is in neutral territory, neither overbought nor oversold.
Is SNDX outperforming the market?
SNDX has a Relative Strength (RS) Rating of 36 out of 99. SNDX is currently lagging the broader market.
Where is SNDX in its 52-week range?
SNDX is trading at $19.00, which is 74% of its 52-week high ($25.58) and 61% above its 52-week low ($8.59).
How volatile is SNDX?
SNDX has a Beta of 0.70 and 52-week volatility of 57%. It's less volatile than the S&P 500 - generally more stable.